DRUG REGULATORY AUTHORITY OF PAKISTAN
Division of Quality Assurance and Laboratory Testing

RAPID ALERT

DRAP ALERT No: Nº I/S/11-26-52

Spurious/Falsified Axtin Soft Gels (Batch # AXAF2301)

Date:, 12th November, 2026

Target Audience:

- Field offices of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Consumers

Problem Statement:

M/s Scotmann Pharmaceuticals (Health & OTC Division) (Nutraceuticals), 5-D, I-10/3 Industrial Area, Islamabad, the authorized manufacturer of **Axtin Softgel**, has reported the availability of a **spurious therapeutic product** in the market bearing a brand name and packaging similar to its duly enlisted product. The resemblance may mislead consumers and stakeholders regarding the authenticity of the product.

Following are the details of the Spurious therapeutic product.

Sr. No.	Name of product	Batch Number	Name of manufacturer	Remarks
1	Axtin Softgels	AXAF2301	Axtin Healthcare Pvt. Ltd., plot no. 12, sector 6, IMT Manesar, Gurgaon, Haryana, India	The product is neither enlisted with DRAP nor manufactured, distributed, or endorsed by the authorized manufacturer, M/s Scotmann Pharmaceuticals (Health & OTC Division), Islamabad.

Risk Statement:

The use of the above-mentioned Spuroius therapeutic product may pose serious safety and quality concerns for public health including therapeutic failure, adverse health consequences, or exposure to unknown safety risks.

DRAP, Islamabad | + 92 051 9255969 | gsms@dra.gov.pk

Action Initiated:

The Regulatory Field Force of Provincial Drug Control Departments has been asked to conduct surveillance activities throughout the supply chain to confiscate the above-mentioned drug products.

Advice for Healthcare Professionals:

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.

Advice for Consumers:

Consumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above-mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Drug Regulatory Authority of Pakistan
محفوظ، موثر اور معیاری اشیائے علاج

DRAP, Islamabad
+ 92 051 9255969
gsms@dra.gov.pk